Sign in
LBPS Stock Price, Chart, Stats & News
4D pharma plc
Save
–
Market cap
–
Current P/E
–
Forward P/E
LBPS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -4370.33% |
Pretax margin | -4451.25% |
Net margin | -4448.19% |
Effective tax rate | 0.07% |
ROA | -54.32% |
ROE | -105.78% |
D/E | 0.39x |
Interest coverage ratio | -54.01x |
LBPS valuation
P/E | – |
P/S | – |
P/B | 0.52x |
P/CF | -0.44x |
P/FCF | – |
P/OCF | -0.44x |
PEG | -0.01x |
EV multiple | -0.27x |
About
4D pharma plc, headquartered in Leeds, UK, and founded in 2014 (originally Schosween 18 Limited), functions as a biopharmaceutical firm dedicated to pioneering live biotherapeutic products (LBPs). The company's diverse pipeline includes several therapeutic candidates aimed at various significant health issues: MRx0518 is being developed to address cancer and immune-oncology diseases. MRx-4DP0004 targets asthma.
Similar securities
Based on sector and market capitalization
Report issue